Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Septerna, a clinical-stage biotech company focused on GPCR-targeted drug discovery, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Jeffrey Finer, M.D., Ph.D., the company's CEO and co-founder, will deliver a presentation on Tuesday, January 14, 2025, at 3:45 p.m. PT in San Francisco. The presentation will be accessible via live webcast through Septerna's website and will remain available for 30 days afterward.
Septerna, una società biotecnologica in fase clinica focalizzata sulla scoperta di farmaci mirati ai GPCR, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare. Jeffrey Finer, M.D., Ph.D., CEO e co-fondatore dell'azienda, terrà una presentazione martedì 14 gennaio 2025, alle 15:45 PT a San Francisco. La presentazione sarà accessibile tramite webcast live attraverso il sito web di Septerna e resterà disponibile per 30 giorni successivi.
Septerna, una empresa biofarmacéutica en etapa clínica centrada en la descubrimiento de fármacos dirigidos a GPCR, ha anunciado su participación en la 43ª Conferencia Anual J.P. Morgan Healthcare. Jeffrey Finer, M.D., Ph.D., el CEO y cofundador de la empresa, dará una presentación el martes 14 de enero de 2025, a las 3:45 p.m. PT en San Francisco. La presentación estará disponible a través de una transmisión en vivo en el sitio web de Septerna y permanecerá accesible durante 30 días después.
Septerna는 GPCR 타겟 의약품 개발에 주력하는 임상 단계의 생명공학 회사로, 제43회 JP 모건 헬스케어 컨퍼런스에 참여한다고 발표했습니다. Jeffrey Finer 박사, 즉 CEO이자 공동 창립자는 2025년 1월 14일 화요일 오후 3시 45분 PT에 샌프란시스코에서 발표를 진행합니다. 발표는 Septerna 웹사이트를 통해 생중계로 시청 가능하며, 이후 30일간 계속해서 이용할 수 있습니다.
Septerna, une entreprise biopharmaceutique en phase clinique axée sur la découverte de médicaments ciblant les GPCR, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare. Jeffrey Finer, M.D., Ph.D., le PDG et co-fondateur de l'entreprise, fera une présentation le mardi 14 janvier 2025, à 15h45 PT à San Francisco. La présentation sera accessible via un webcast en direct sur le site web de Septerna et restera disponible pendant 30 jours par la suite.
Septerna, ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf GPCR-orientierte Arzneimittelentdeckung konzentriert, hat seine Teilnahme an der 43. Jahreskonferenz von J.P. Morgan Healthcare angekündigt. Jeffrey Finer, M.D., Ph.D., der CEO und Mitbegründer des Unternehmens, wird am Dienstag, den 14. Januar 2025, um 15:45 Uhr PT in San Francisco eine Präsentation halten. Die Präsentation wird über einen Live-Webcast auf der Website von Septerna erreichbar sein und bleibt 30 Tage lang verfügbar.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 3:45 p.m. PT in San Francisco.
A live webcast will be available in the Investors & Media section of the company’s website at www.septerna.com and will be archived for 30 days following the presentation.
About Septerna
Septerna, Inc. is a clinical-stage biotechnology company pioneering a new era of GPCR drug discovery powered by its proprietary Native Complex Platform™. Its industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of its deep pipeline of oral small molecule product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Septerna was launched by preeminent drug discovery company builders and scientific leaders in the biochemistry, structural biology, and pharmacology of GPCRs. For more information, please visit www.septerna.com.
Investor Contact:
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com
Media Contact:
Carly Scaduto
Carly Scaduto Consulting
Carly@carlyscadutoconsulting.com
FAQ
When is Septerna (SEPN) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Septerna's J.P. Morgan Healthcare Conference presentation?
Who will represent Septerna at the 2025 J.P. Morgan Healthcare Conference?
What is Septerna's current business focus in the biotech industry?
